Molecular Instruments and Abcam Announce Broad Compatibility of the HCR™ HiFi Encoder with Abcam's Best-in-Class RabMAb® and Mouse Antibody Portfolio
Metabolism Assays Market Size Projected to Reach USD 3.1 Billion by 2034, Growing Steadily at 6.7% CAGR | Report by Transparency Market Research, Inc
Danaher completes $5.7 billion acquisition of Abcam
Danaher Completes Acquisition of Abcam
Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales
Statement from Dr. Jonathan Milner on the suspension of the “Vote AGAINST” campaign
Jonathan Milner Issues Statement Responding to the Glass Lewis Report
Jonathan Milner Issues Statement Responding to ISS Report
Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the Company
Exlusive: Why Abcam founder believes Danaher's acquisition offer falls short
ABCAM INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abcam plc - ABCM
Jonathan Milner issues Open Letter to shareholders of Abcam plc
GMED or ABCM: Which Is the Better Value Stock Right Now?
Jonathan Milner issues Open Letter to shareholders of Abcam plc
Abcam plc Statement on Dr. Jonathan Milner's Announcement
Dr. Jonathan Milner opposes Danaher's acquisition of Abcam and calls for EGM to replace Board
Abcam plc Interim Results for the Six-Month Period Ended 30 June 2023
ABCAM INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abcam plc - ABCM
Danaher Buys Abcam for $5.7 Billion to Expand Its Product Offerings
ABCM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Abcam plc Is Fair to Shareholders
Danaher acquires biotech supplier Abcam for $5.7B
Medical tech firm Danaher to buy Abcam in deal valued at $5.7 bln
Danaher to Buy Abcam in $5.7 Billion Deal. Investors Don't Like the Premium.
Abcam agrees to be acquired by Danaher in $5.7B deal
Danaher to acquire Abcam for $24.00 per Share
Danaher to Acquire Abcam
Exclusive: Danaher in the lead to acquire biomedical equipment vendor Abcam-sources
Are Medical Stocks Lagging Abcam (ABCM) This Year?
Abcam plc: All Resolutions Withdrawn at Abcam's EGM
Why Shares of Abcam Are Jumping Friday
Are You Looking for a Top Momentum Pick? Why Abcam PLC Sponsored ADR (ABCM) is a Great Choice
3 Stocks With Upgraded Broker Ratings for Robust Returns
Is Abcam (ABCM) Outperforming Other Medical Stocks This Year?
Why Shares in Abcam Surged This Week
Abcam: Nosebleed Valuations, Flat Growth Profile Justify Hold Rating
How Much Upside is Left in Abcam PLC Sponsored ADR (ABCM)? Wall Street Analysts Think 27.55%
Abcam plc (ABCM) Q4 2022 Earnings Call Transcript
Abcam to Report Full Year Results on Monday, March 20, 2023
NanoString and Abcam Expand Collaboration to Advance Spatial Multiomics Research
Abcam: A Good Growth Stock In The Healthcare Market
Abcam plc (ABCM) Q4 2022 Earnings Call Transcript
Abcam (ABCM) CEO, Alan Hirzel on Q4 2021 Results - Earnings Call Transcript
Abcam Collaborates With Twist Bioscience to Enhance Antibody Discovery for Diagnostic and Research Applications
4 High Financial Strength Stocks Trading Near Historical Low Price-Book Ratios
Abcam jumps as it snaps up major supplier BioVision
Abcam To Acquire Supplier BioVision For $340M In Cash
Abcam to Acquire BioVision for $340 million
New Strong Sell Stocks for July 29th
Proteomics International engages Abcam to manufacture PromarkerD reagents
Abcam opens new US facility in Boston, MA